Sulfur-Containing Cobalamin Derivatives for CblC Defect Bypass
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for vitamin B12 deficiencies, particularly in individuals with genetic defects or impaired uptake, fail to effectively enhance intracellular cobalamin processing and enzymatic reactions, leading to conditions like homocystinuria and methylmalonic aciduria, and are ineffective in addressing age-related deficiencies and cognitive impairments.
Innovation Solution
Development of sulfur-containing cobalamin derivatives with Co—S or Co—C axial bonds that enhance the activity of the CblC enzyme, bypassing genetic defects and improving intracellular cobalamin utilization, formulated for oral or parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vitamin B12 treatments are administered, then basic nutritional needs may be met, but they fail to effectively enhance intracellular cobalamin processing and enzymatic reactions in individuals with genetic defects or impaired uptake
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of cobalamin molecules, specifically introducing sulfur-containing ligands (thiolates) in place of conventional ligands like cyanide or hydroxide. This structural parameter change creates derivatives with enhanced reactivity and improved ability to engage with CblC enzyme, thereby resolving the contradiction between reliable cobalamin processing and adaptability to genetic defects.
Solution Approach 2:
The sulfur-containing cobalamin derivatives act as intermediaries that bridge the gap between dietary cobalamin and the CblC enzyme processing pathway. These modified molecules serve as enhanced substrates that can be more effectively processed by CblC, even when the enzyme's natural substrate recognition is impaired by genetic defects, thus improving both reliability and adaptability.
2Reliability
If sulfur-containing cobalamin derivatives are used to enhance CblC enzyme activity, then intracellular cobalamin utilization is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
By changing the chemical parameters of cobalamin (introducing sulfur ligands), the patent creates molecules that are inherently more reactive and better utilized by CblC enzyme. This single parameter change addresses multiple therapeutic needs simultaneously, improving intracellular utilization without requiring complex combination therapies or multi-step treatment protocols.
3Reliability
If existing cobalamin treatments are administered, then general vitamin B12 deficiency may be addressed, but they are ineffective in restoring normal CblC protein function in the absence or defect of CblC gene
Solution Approach 1:
The sulfur-containing cobalamin derivatives serve as specialized intermediaries that can interact with CblC enzyme even when the enzyme is defective or absent. These modified molecules can potentially compensate for CblC dysfunction by alternative mechanisms, such as direct donation of cobalamin to downstream enzymes or stabilization of alternative processing pathways, thereby restoring function despite genetic defects.
Solution Approach 2:
The patent creates copies of natural cobalamin with modified structures that better suit the needs of impaired CblC processing. These synthetic analogs replicate the essential functions of natural cobalamin while incorporating improvements that bypass the defective CblC pathway, enabling therapeutic effect even when the original processing mechanism is compromised.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cobalamin derivatives exhibit improved bioactivity, effectively treating and preventing neurological manifestations, enhancing enzymatic reactions, and supporting cognitive function by restoring normal CblC protein function, even in the absence of the CblC gene.
Implementation Method 1
The compound is a cobalamin derivative of formula (I) wherein X is a ligand having a formula selected from the group consisting of: —(CH2)1-5—S—(CH2)0-3—CH3, —S—(CH2)1-5—NH2
Data Source
AI summary
The present invention concerns cobalamin derivatives of formula (I)wherein X is a ligand having a formula selected from among:—(CH2)1-5—S—(CH2)0-3—CH3, —S—(CH2)1-5—NH2 andfurther wherein R1 is H, methyl or ethyl, R2 isand R3 is —H orand its use in diseases caused by lack of vitamin B12 support.